Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Y. Grace Wang"'
Autor:
Teresa L. Steininger, Murray W. Johns, D. Menno, Abby Chen, Judi Profant, Y. Grace Wang, Jed Black, Susan B. Morris
Publikováno v:
Sleep Medicine. 89:78-84
The Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) measures daytime sleepiness, but had not previously been validated in children12 years of age.Data from a sodium oxybate (SXB) study in pediatric participants with narcolepsy with c
Autor:
Lawrence P. Carter, Jack E. Henningfield, Edward M. Sellers, Yuan Lu, Debra Kelsh, Bradley Vince, Y. Grace Wang
Publikováno v:
Journal of Psychopharmacology (Oxford, England)
Background: This study evaluated the human abuse potential of solriamfetol (formerly JZP-110), a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects. Methods: Adults with a recent history of recreational polydr
Autor:
Carter, Lawrence P, Henningfield, Jack E, Y Grace Wang, Lu, Yuan, Kelsh, Debra, Vince, Bradley, Sellers, Edward
Supplemental material, suppl._mat for A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor by Lawrence P Carter, Jack E Henni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c2c8bae708eb006075d840620afa410
Autor:
Y. Grace Wang, Steve Hwang, Jed Black, Khadra Benmedjahed, Christopher J. Evans, Jérémy Lambert, Murray W. Johns
Publikováno v:
Nature and Science of Sleep
Y Grace Wang,1 Khadra Benmedjahed,2 Jérémy Lambert,2 Christopher J Evans,3 Steve Hwang,3 Jed Black,1,4 Murray W Johns5 1Clinical Development, Jazz Pharmaceuticals, Palo Alto, CA, USA; 2Patient-Centered Outcomes, Mapi, Lyon, France; 3Endpoint Outcom
Autor:
Jérémy Lambert, Jed Black, Khadra Benmedjahed, Christopher J. Evans, Murray W. Johns, Steve Hwang, Y. Grace Wang
Publikováno v:
Sleep medicine. 32
Objective The objective of this study was to review patient-reported outcome measures assessing excessive daytime sleepiness (EDS) or cataplexy in children or adolescents to determine their usefulness and limitations in pediatric narcolepsy assessmen
Autor:
Robert M. Bennett, Y. Grace Wang, Chinglin Lai, Beverly A. Benson, Michael Spaeth, Ernest Choy
Publikováno v:
Annals of the Rheumatic Diseases
Background Fibromyalgia is characterised by chronic musculoskeletal pain and multiple symptoms including fatigue, multidimensional function impairment, sleep disturbance and tenderness. Along with pain and fatigue, non-restorative sleep is a core sym
Publikováno v:
Journal of Clinical Sleep Medicine. :365-371
Study Objectives: This study reviewed the cumulative postmarketing and clinical safety experience with sodium oxybate (Xyrem®), a treatment approved for cataplexy and excessive daytime sleepiness in narcolepsy. Study objectives were to investigate t
Autor:
Andrew J. Holman, Diane Guinta, I. Jon Russell, Y. Grace Wang, Sarah Alvarez-Horine, Todd J. Swick
Publikováno v:
PainReferences. 152(5)
This 14-week, phase 3, double-blind, randomized, controlled trial evaluated sodium oxybate (SXB) 4.5 and 6g per night versus placebo in patients with fibromyalgia (FM). SXB is the sodium salt of γ-hydroxybutyrate (GHB). GHB is an endogenous compound
This study reviewed the cumulative postmarketing and clinical safety experience with sodium oxybate (Xyrem), a treatment approved for cataplexy and excessive daytime sleepiness in narcolepsy. Study objectives were to investigate the occurrence of abu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1c2587ceb8e46f7b19b6d35edb016636
https://europepmc.org/articles/PMC2725257/
https://europepmc.org/articles/PMC2725257/
Publikováno v:
Journal of Clinical Sleep Medicine. :415-416
In the paper noted above, which was published in 2009, we reported safety information for patients on sodium oxybate (Xyrem®), including the numbers of patients with a prescription for sodium oxybate who had died from all causes (i.e., whether or no